- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01595269
The Clinical and Economic Impacts of e-Heath on Diabetes (eHealthDM)
May 8, 2012 updated by: Dr. Danièle Pacaud
This project addresses the following Null Hypotheses:
- There will be no difference will be found in the use of the search engine and the information accessed among the three education modes.
- There will be no difference in education mode's effect on metabolic control, self-care management practices, and medical resource utilization.
- There will be no difference in the economic impact on the health care system based on differing education modes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In addition to the face-to-face education process currently used at the CHR, this project will develop two modes of eHealth education.
Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals.
These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information.
This allows for the tracking of the type and amounts of diabetes information accessed by participants.
Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information.
Education mode 2 will be assessed and approved by CHR.
Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts).
In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team.
Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board).
New sites and articles will be added on an ongoing basis.
Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
Study Type
Interventional
Enrollment (Actual)
79
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Lethbridge, Alberta, Canada
- Calgary Health Region's offices across southwestern Alberta
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18 or older
- Literate
- Not participating in other clinical trials
- Diabetes diagnosed within the last three months
- Type 2 diabetes
- No medical conditions that could compromise metabolic control
- No linguistic, cognitive or psychosocial barriers that would hinder study completion
- Computer and internet literate
- Access to high-speed internet
Exclusion Criteria:
- Under the age of 18
- Not literate
- Participating in other clinical trials
- Diabetes diagnosed greater than three months ago
- Type 1 diabetes
- Gestational diabetes
- Additional medical conditions that could compromise metabolic control
- Linguistic, cognitive or psychosocial barriers that would hinder study completion
- Not computer and internet literate
- No access to high-speed internet
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Education mode 1 (control)
Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals.
These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information.
This allows for the tracking of the type and amounts of diabetes information accessed by participants.
|
In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
|
Active Comparator: Education mode 2 (static interface)
Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information.
Education mode 2 will be assessed and approved by CHR.
|
In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
|
Active Comparator: Education mode 3 (dynamic interface)
Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts).
In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team.
Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board).
New sites and articles will be added on an ongoing basis.
Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
|
In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in A1C
Time Frame: baseline, 3, 6, 9, 12 months
|
A1C is a measure of metabolic control in diabetes.
For this study changes in A1C from baseline to 3, 6, 9 and 12 months were measured.
All A1C were measured in provincial laboratories using 6.1% as the upper limit of normal for individuals without diabetes.
|
baseline, 3, 6, 9, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
a reduction in the cost of delivering health information and education processes
Time Frame: baseline and 12 months
|
Secondary effects could include a change in the cost of delivering health information and education processes.
Potential changes to self-care management practices of people with type II diabetes could lead to a reduced utilization of the heath care system resulting in a positive economic impact.
|
baseline and 12 months
|
Changes in Diabetes Knowledge
Time Frame: baseline, 3, 6, 9, 12 months
|
Changes in diabetes knowledge from baseline to 3, 6, 9, and 12 months will be measured using a 23 item multiple choice questionnaire devolopped by Fitzgerald et al 1998.
|
baseline, 3, 6, 9, 12 months
|
Changes in Diabetes self-care activities
Time Frame: Baseline, 3, 6, 9 and 12 months
|
Changes in diabetes self-care activities from base line to 3, 6, 9, and 12 months will be measured the diabetes self-care activities tool evaluated by Toobert at al (2000).
|
Baseline, 3, 6, 9 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Angela M Downey, PhD, CMA, FCMA, University of Lethbridge
- Principal Investigator: Helen Kelley, PhD, University of Lethbridge
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
March 3, 2011
First Submitted That Met QC Criteria
May 8, 2012
First Posted (Estimate)
May 10, 2012
Study Record Updates
Last Update Posted (Estimate)
May 10, 2012
Last Update Submitted That Met QC Criteria
May 8, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LAWSON-686
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on eHealth education
-
Hiroshima UniversityNorth South University, BangladeshCompleted
-
University of MichiganCenters for Disease Control and PreventionRecruitingGlaucomaUnited States
-
University of PennsylvaniaFox Chase Cancer Center; Columbia University; Thomas Jefferson UniversityEnrolling by invitationCardiovascular Diseases | Cancer | Genetic DiseaseUnited States
-
Duke Kunshan UniversityCompletedSmoking Cessation | Lifestyle, HealthyChina
-
Texas Tech UniversityCompleted
-
Dartmouth-Hitchcock Medical CenterCompletedObesity | Videoconferencing | mHealth | Technology | Behavior, HealthUnited States
-
UKK InstituteUniversity of Eastern Finland; North Karelia Hospital DistrictUnknown
-
University of MiamiNational Institute on Drug Abuse (NIDA)CompletedDrug Use | Sexual Risk Behavior | Family FunctioningUnited States
-
University of MinnesotaEnrolling by invitationParent-Child Relations | Parents | Behavior Problem | Behavior, ChildUnited States
-
University of Alabama at BirminghamCompletedCancer | Overweight and ObesityUnited States